Citigroup Inc Genmab A/S Call Options Transaction History
Citigroup Inc
- $163 Billion
- Q4 2024
Call Options
1 transactions
Others Institutions Holding GMAB
# of Institutions
248Shares Held
61.3MCall Options Held
159KPut Options Held
38K-
Alliancebernstein L.P. New York, NY14.9MShares$360 Million0.11% of portfolio
-
Black Rock Inc. New York, NY5.08MShares$122 Million0.0% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il3.09MShares$74.5 Million0.01% of portfolio
-
Orbis Allan Gray LTD Hamilton, D02.82MShares$67.9 Million0.4% of portfolio
-
Morgan Stanley New York, NY2.81MShares$67.6 Million0.0% of portfolio
About GENMAB A/S
- Ticker GMAB
- Exchange OTC
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 658,292,992
- Market Cap $15.9B
- Description
- Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphoc...